Purpose Of Review: Profiling bladder tumors using high-density microarrays has recently become possible. We review recent reports on the use of profiling for the prediction of various clinical courses in bladder cancer. We also stress the methods and materials needed to translate such molecular profiles into clinically useful tests.
Recent Findings: Using gene expression microarrays, it has been possible to identify signatures that predict various properties of bladder cancer such as stage, grade, progression, and likelihood of metastases. Using arrays for genomic instability, similar properties have been examined, but the effectiveness seems to be less than that of gene expression. Some of genes identified also work as predictors using immunohistochemistry.
Summary: The signatures or molecular profiles for some of these arrays are now being tested in multicenter studies with the purpose of introducing these into the clinic, for planning of follow-up and treatment selection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/01.mou.0000240313.16324.d3 | DOI Listing |
Ann Oncol
February 2025
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Electronic address:
Background: We predicted the number of cancer deaths and rates for 2025 in the European Union (EU), its five most populous countries, and the UK, focusing on breast cancer.
Materials And Methods: We derived population data and death certificates for all cancers and major sites for the EU, France, Germany, Italy, Poland, Spain, and the UK since 1970, from the World Health Organization and United Nations databases. Estimates for 2025 were computed by linear regression on recent trends identified through Poisson joinpoint regression, considering the slope of the most recent trend segment.
Eur Urol
March 2025
Unit of Urology, Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Eur Urol
March 2025
Division of Urology, Department of Surgical Sciences, Torino School of Medicine, Torino, Italy.
Transl Oncol
March 2025
Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Gansu Urological Clinical Center, Lanzhou, China. Electronic address:
Background: Mesenchymal stem cells (MSCs), due to their tumor-targeting homing properties, are present in the tumor microenvironment (TME) and influence the biological behaviors of tumors. The purpose of this paper is to establish a signature based on the MSC secretome to predict the prognosis and treatment of bladder cancer (BLCA).
Methods: The presence of MSCs in BLCA was validated through flow cytometry and multiplex fluorescence immunohistochemistry (mFIHC), and the relationships between MSCs and clinical characteristics were explored.
Ecotoxicol Environ Saf
March 2025
Department of Radiobiology and Hygiene Management, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan. Electronic address:
In Japan, several workers were diagnosed with bladder cancer 10-40 years after exposure to 4,4'-methylenebis(2-chloroaniline) (MOCA), mainly through the skin. MOCA also induces bladder cancer in dogs and nonbladder (breast, liver, lung) cancers in rodents. MOCA with S9 fractions contains mutagenic metabolites after catalysis by N-acetyl transferase (NAT).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!